|Cancer Antigen 125|
To monitor treatment for ovarian cancer or to detect recurrence; sometimes to evaluate a lump located in the pelvic area (pelvic mass); not recommended for screening asymptomatic women.
To detect the presence of inflammation caused by one or more conditions such as infections, tumors or autoimmune diseases.
To screen for, help diagnose and/or monitor several diseases and conditions, such as kidney disorders or urinary tract infections (UTIs)
|Carcinoembryonic Antigen (CEA)|
This test is used primarily to monitor cancer treatment, including response to therapy and recurrence; as an indicator of the amount of cancer or size of tumor present (tumor burden) and to assist in cancer staging.
|Cancer Antigen 19-9|
This test is used primarily to monitor response to pancreatic cancer treatment and to watch for recurrence; sometimes to aid in the diagnosis of pancreatic cancer.
|Cancer Antigen 15-3|
Cancer antigen 15-3 (CA 15-3) is a protein that is produced by normal breast cells. In many people with cancerous breast tumors, there is an increased production of CA 15-3 and the related cancer antigen 27.29.
|Comprehensive Metabolic Panel (CMP)|
The comprehensive metabolic panel (CMP) is used as a broad screening tool to evaluate organ function and check for conditions such as diabetes, liver disease, and kidney disease. Includes 14 tests.
|CBC w / Differential|
The complete blood count (CBC) is often used as a broad screening test to determine an individual’s general health status including cardiac risk.
|CRP High Sensitivity|
The high-sensitivity CRP test measures low levels of CRP in the blood to identify low levels of inflammation that are associated with risk of developing cardiovascular disease (CVD).